Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese
Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the in Han...
Saved in:
| Published in | Pharmacogenomics Vol. 11; no. 3; pp. 349 - 356 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Future Medicine Ltd
01.03.2010
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1462-2416 1744-8042 1744-8042 |
| DOI | 10.2217/pgs.09.162 |
Cover
Loading…
| Abstract | Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the
in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.
We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The
,
,
and
genotypes were determined.
We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10
) patients. In addition,
,
and
also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).
Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in
carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the
carrier and caution should also be exercised for LTG. |
|---|---|
| AbstractList | Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.
We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined.
We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 x 10(-4)) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).
Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG. Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ. Materials & methods: We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined. Results: We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10-4) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3). Conclusion: Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG. Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ. Materials & methods: We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined. Results: We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 10 super(-4)) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3). Conclusion: Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG. Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ. We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The , , and genotypes were determined. We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10 ) patients. In addition, , and also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3). Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the carrier and caution should also be exercised for LTG. Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ. Materials & methods: We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined. Results: We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10.sup.-4 ) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3). Conclusion: Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG. Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.AIMSCompared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly associated with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent. Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.We carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined.MATERIALS & METHODSWe carried out a case-control association study. We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, respectively, for more than 3 months without the adverse reactions, and 93 normal subjects from the general population. The HLA-A, B, C and DRB1 genotypes were determined.We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 x 10(-4)) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).RESULTSWe found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 x 10(-4)) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).Our results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG.CONCLUSIONOur results indicate that OXC, PHT and LTG, which possess an aromatic ring just as CBZ does, when causing SJS/TEN, share a common risk allele. Aromatic antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease. We suggest that aromatic antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG. |
| Audience | Academic |
| Author | Hung, Shuen-Iu Hui, Rosaline Chung-yee Chu, Chia-Yu Chung, Wen-Hung Liu, Zhi-Sheng Hsih, Mo-Song Chen, Yuan-Tsong Chen, Chien-Hsiun |
| AuthorAffiliation | Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, Nankang, Taipei 11529, Taiwan and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei Taiwan Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan Department of Neurology, Wuhan Children s Hospital, Wuhan, China Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, Nankang, Taipei 11529, Taiwan. chen0010@ibms.sinica.edu.tw |
| AuthorAffiliation_xml | – name: Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, Nankang, Taipei 11529, Taiwan. chen0010@ibms.sinica.edu.tw – name: Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan – name: Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan – name: Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, Nankang, Taipei 11529, Taiwan and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei Taiwan – name: Department of Neurology, Wuhan Children s Hospital, Wuhan, China – name: Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan |
| Author_xml | – sequence: 1 givenname: Shuen-Iu surname: Hung fullname: Hung, Shuen-Iu – sequence: 2 givenname: Wen-Hung surname: Chung fullname: Chung, Wen-Hung – sequence: 3 givenname: Zhi-Sheng surname: Liu fullname: Liu, Zhi-Sheng – sequence: 4 givenname: Chien-Hsiun surname: Chen fullname: Chen, Chien-Hsiun – sequence: 5 givenname: Mo-Song surname: Hsih fullname: Hsih, Mo-Song – sequence: 6 givenname: Rosaline Chung-yee surname: Hui fullname: Hui, Rosaline Chung-yee – sequence: 7 givenname: Chia-Yu surname: Chu fullname: Chu, Chia-Yu – sequence: 8 givenname: Yuan-Tsong surname: Chen fullname: Chen, Yuan-Tsong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20235791$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkuLFDEUhQsZcR668QdIoQtFqDbPeiyHRh1lwIW6DunkVk_GVFImVWLv_OneokbBoZEskku-c_I497w4CTFAUTylZMMYbd6M-7wh3YbW7EFxRhshqpYIdoJrUbOKCVqfFuc53xLCaC3Io-KUEcZl09Gz4tc2DkMMZXL5W6m9Bw-lC6VOcdCTM6UOk4PReRixqmya97htZwO2_DzBDwi5-hhvQkaLfAgWZYAaW07xJ6pRaSEN2pcBTIr-kF1e7K90KLc3LkCGx8XDXvsMT-7mi-Lru7dftlfV9af3H7aX15WRrJ4qCbZpbbdr26azPaEcBGc7zWnftVrSpm0ot5LUst2ZmlgOxHCiZWOoJBKk5hfFy9V3TPH7DHlSg8sGvNcB4pxVwzkXneA1kq_-S1LCRcsJoQv6_B56G-cU8B2KsYVpOUPoxQrttQflQh-npM3iqS4Zk0TITgikNkcoHBYGZzDwHkP4V_Ds7ux5N4BVY3KDTgf1J1sEXq8A_nzOCfq_CCVqaRyFjaNIp7BxECb3YOMm7IAY8BrOH5fUq6SfpzlBNg6CAbVWeCNnMOBjwt_xBtdU |
| CitedBy_id | crossref_primary_10_1146_annurev_genom_083115_022324 crossref_primary_10_1016_j_jaci_2011_12_990 crossref_primary_10_5698_1535_7511_11_6_189 crossref_primary_10_1111_epi_13566 crossref_primary_10_1177_147323001204000140 crossref_primary_10_3343_alm_2014_34_5_372 crossref_primary_10_1007_s10309_011_0172_z crossref_primary_10_2217_pgs_2017_0016 crossref_primary_10_9740_mhc_2015_03_078 crossref_primary_10_1002_14651858_CD010891 crossref_primary_10_1038_s41397_021_00247_3 crossref_primary_10_3389_fphar_2022_1061419 crossref_primary_10_1155_2014_565320 crossref_primary_10_2217_pgs_12_108 crossref_primary_10_1177_2042098613499791 crossref_primary_10_1016_j_jaip_2013_11_005 crossref_primary_10_1146_annurev_pharmtox_052120_014115 crossref_primary_10_1159_000448217 crossref_primary_10_3390_genes12060904 crossref_primary_10_1038_clpt_2014_159 crossref_primary_10_1038_s41598_017_08876_0 crossref_primary_10_1007_s00251_017_1007_5 crossref_primary_10_2217_bmm_11_75 crossref_primary_10_1007_s00103_013_1827_x crossref_primary_10_2174_1381612825666191107105440 crossref_primary_10_1016_j_jid_2017_11_027 crossref_primary_10_1007_s40291_018_0330_3 crossref_primary_10_1038_nrneurol_2013_245 crossref_primary_10_1038_jhg_2013_37 crossref_primary_10_1111_epi_12217 crossref_primary_10_1007_s11882_013_0418_0 crossref_primary_10_1111_liv_14004 crossref_primary_10_1016_j_eplepsyres_2020_106391 crossref_primary_10_1097_FPC_0000000000000531 crossref_primary_10_52547_jccs_3_1_19 crossref_primary_10_1016_j_dsi_2013_09_002 crossref_primary_10_1080_1744666X_2019_1612241 crossref_primary_10_1212_WNL_0000000000004008 crossref_primary_10_2217_pgs_15_4 crossref_primary_10_1038_mp_2011_146 crossref_primary_10_3892_br_2014_272 crossref_primary_10_1007_s00198_016_3568_9 crossref_primary_10_3389_fgene_2014_00478 crossref_primary_10_1111_jdv_16339 crossref_primary_10_1007_s00228_013_1563_z crossref_primary_10_1038_tpj_2016_5 crossref_primary_10_1016_j_seizure_2018_06_024 crossref_primary_10_1111_epi_12564 crossref_primary_10_3389_fphar_2022_832048 crossref_primary_10_2174_1381612825666191107161912 crossref_primary_10_1002_14651858_CD010891_pub2 crossref_primary_10_1097_ACI_0b013e3283630cc2 crossref_primary_10_5497_wjp_v3_i4_174 crossref_primary_10_1097_01_EWX_0000491262_03254_04 crossref_primary_10_2217_pgs_2017_0041 crossref_primary_10_3389_fphar_2020_567048 crossref_primary_10_1016_j_seizure_2019_07_003 crossref_primary_10_1097_FPC_0000000000000306 crossref_primary_10_1016_j_seizure_2012_06_014 crossref_primary_10_1111_j_1742_7843_2011_00681_x crossref_primary_10_1089_cap_2023_0064 crossref_primary_10_1111_bcp_14667 crossref_primary_10_3892_etm_2018_5801 crossref_primary_10_1016_j_seizure_2018_12_011 crossref_primary_10_1080_17425255_2025_2455388 crossref_primary_10_3349_ymj_2016_57_1_118 crossref_primary_10_1097_FPC_0000000000000153 crossref_primary_10_1016_j_biopha_2017_04_015 crossref_primary_10_1002_cpt_1190 crossref_primary_10_1586_14737175_2015_1083424 crossref_primary_10_12688_f1000research_24748_1 crossref_primary_10_1016_j_coi_2016_05_003 crossref_primary_10_2174_1574886318666230529123200 crossref_primary_10_15789_1563_0625_DHM_2396 crossref_primary_10_1080_15569527_2016_1218501 crossref_primary_10_1111_bcp_14533 crossref_primary_10_2217_pgs_2017_0189 crossref_primary_10_1097_MD_0000000000015553 crossref_primary_10_1111_ijcp_14273 crossref_primary_10_1016_j_seizure_2022_09_011 crossref_primary_10_1038_tpj_2016_10 crossref_primary_10_1146_annurev_med_050913_022745 crossref_primary_10_1038_s41397_024_00326_1 crossref_primary_10_2217_pgs_2019_0040 crossref_primary_10_3805_eands_3_51 crossref_primary_10_1007_s12016_017_8654_z crossref_primary_10_1080_08927022_2014_929127 crossref_primary_10_1002_cpt_683 crossref_primary_10_1007_s11095_018_2472_8 crossref_primary_10_1177_0004867412455702 crossref_primary_10_1016_j_aat_2016_02_001 crossref_primary_10_1080_17425255_2021_1946514 crossref_primary_10_3389_fphar_2024_1433506 crossref_primary_10_1136_bmjpo_2017_000088 crossref_primary_10_1111_epi_13509 crossref_primary_10_2217_pgs_2022_0177 crossref_primary_10_1056_NEJMc1105467 crossref_primary_10_1016_j_neulet_2017_01_014 crossref_primary_10_2133_dmpk_DMPK_10_RV_089 crossref_primary_10_2217_pgs_13_180 crossref_primary_10_1111_dth_14176 crossref_primary_10_1007_s00228_018_02618_5 crossref_primary_10_1016_j_jaip_2018_07_003 crossref_primary_10_1016_j_tiv_2022_105383 crossref_primary_10_1111_j_1346_8138_2010_01196_x crossref_primary_10_12677_acm_2024_1492540 crossref_primary_10_3389_fphar_2017_00879 crossref_primary_10_1021_tx200168d crossref_primary_10_3389_fphar_2021_588063 crossref_primary_10_1016_j_yebeh_2010_11_022 crossref_primary_10_1016_j_iac_2017_07_007 crossref_primary_10_1038_clpt_2013_103 crossref_primary_10_1517_17425255_2014_872630 crossref_primary_10_3390_biomedicines11010177 crossref_primary_10_2217_pgs_14_65 crossref_primary_10_1248_bpb_b24_00072 crossref_primary_10_1212_WNL_0000000000003453 crossref_primary_10_3389_fmed_2021_652091 crossref_primary_10_2217_pgs_2017_0090 crossref_primary_10_1097_MJT_0000000000000070 crossref_primary_10_1111_all_14127 crossref_primary_10_1007_s00228_017_2250_2 crossref_primary_10_1016_j_eplepsyres_2020_106321 crossref_primary_10_1111_ijd_12570 crossref_primary_10_1111_ijd_17104 crossref_primary_10_1212_WNL_0000000000001034 crossref_primary_10_1080_17425255_2020_1780209 crossref_primary_10_1097_FPC_0000000000000118 crossref_primary_10_3389_fphar_2020_00078 crossref_primary_10_1016_j_jaci_2011_08_013 crossref_primary_10_1016_j_jaci_2015_05_050 crossref_primary_10_1038_ejhg_2016_114 crossref_primary_10_1007_s40521_020_00244_0 crossref_primary_10_2217_pgs_11_165 crossref_primary_10_1021_acs_jmedchem_9b01297 crossref_primary_10_22159_ajpcr_2022_v15i4_44455 crossref_primary_10_3389_fphar_2020_00527 crossref_primary_10_1007_s00228_013_1627_0 crossref_primary_10_2217_pgs_2021_0126 crossref_primary_10_1016_j_nrleng_2015_03_021 crossref_primary_10_1016_j_jaci_2022_12_005 crossref_primary_10_1016_j_survophthal_2016_01_004 crossref_primary_10_1155_2014_824343 crossref_primary_10_2217_pgs_2023_0173 crossref_primary_10_3390_ijms222111696 crossref_primary_10_1212_WNL_0b013e3182915be2 crossref_primary_10_3389_fimmu_2014_00597 crossref_primary_10_3389_fphar_2024_1411487 crossref_primary_10_15406_ppij_2021_09_00334 crossref_primary_10_1111_epi_14599 crossref_primary_10_1016_j_jaci_2010_11_046 crossref_primary_10_3389_fgene_2021_641905 crossref_primary_10_1111_tan_13183 crossref_primary_10_3389_fneur_2019_00614 crossref_primary_10_1097_FPC_0b013e32834aeedb crossref_primary_10_1155_2018_6431694 crossref_primary_10_1016_S0972_6292_16_30480_6 crossref_primary_10_1097_FPC_0b013e328348c6f2 crossref_primary_10_1146_annurev_pharmtox_010818_021818 crossref_primary_10_1002_phar_2797 crossref_primary_10_1007_s15007_018_1522_1 crossref_primary_10_1111_epi_12049 crossref_primary_10_2217_pgs_12_180 crossref_primary_10_1038_s41576_022_00572_8 crossref_primary_10_1016_j_neurol_2017_11_006 crossref_primary_10_1111_j_1533_2500_2011_00479_x crossref_primary_10_1097_JCP_0b013e31823f87e5 crossref_primary_10_2217_pgs_2016_0164 crossref_primary_10_1212_WNL_0b013e31826aac73 crossref_primary_10_1111_bcp_13294 crossref_primary_10_1016_S1634_7072_14_68868_1 crossref_primary_10_1111_j_1528_1167_2011_03318_x crossref_primary_10_2217_pgs_15_128 crossref_primary_10_1080_08820538_2021_1893764 crossref_primary_10_1016_j_yebeh_2014_05_025 crossref_primary_10_3390_ijms17111890 crossref_primary_10_1136_bjophthalmol_2020_317105 crossref_primary_10_1176_appi_focus_20170044 crossref_primary_10_1159_000366253 crossref_primary_10_1111_all_14174 crossref_primary_10_1111_iji_12304 crossref_primary_10_1016_j_therap_2016_12_009 crossref_primary_10_3389_fphar_2020_00969 crossref_primary_10_1038_s41572_024_00514_0 crossref_primary_10_1097_ACI_0000000000000914 crossref_primary_10_1016_j_nrl_2015_03_005 crossref_primary_10_1016_j_trsl_2012_01_004 crossref_primary_10_3904_kjim_2018_126 crossref_primary_10_1097_CM9_0000000000003250 crossref_primary_10_2217_pgs_14_144 crossref_primary_10_1007_s40257_015_0158_0 crossref_primary_10_1016_j_pediatrneurol_2014_03_021 crossref_primary_10_1002_phar_1398 crossref_primary_10_2217_pgs_11_85 crossref_primary_10_1016_j_seizure_2010_11_014 crossref_primary_10_1186_1471_2377_13_75 crossref_primary_10_3923_ijp_2019_978_985 crossref_primary_10_1097_FPC_0000000000000211 crossref_primary_10_3389_fphar_2022_866903 crossref_primary_10_1016_j_seizure_2011_01_005 crossref_primary_10_1159_000458725 crossref_primary_10_1007_s15014_019_1670_0 crossref_primary_10_3390_ijms17081242 crossref_primary_10_2217_pgs_14_135 crossref_primary_10_47102_annals_acadmedsg_2021326 crossref_primary_10_2217_bmm_13_142 crossref_primary_10_1055_s_0042_1749344 crossref_primary_10_1038_tpj_2013_40 crossref_primary_10_1515_dmpt_2016_0025 crossref_primary_10_1016_j_jaip_2022_02_004 crossref_primary_10_1007_s00415_019_09404_y crossref_primary_10_1016_j_jaad_2013_05_003 crossref_primary_10_1159_000453265 crossref_primary_10_3389_fneur_2019_00001 crossref_primary_10_1111_tan_13530 crossref_primary_10_1016_j_ejpn_2012_04_009 crossref_primary_10_3389_fphar_2018_01436 |
| Cites_doi | 10.1159/000091834 10.1073/pnas.0409500102 10.1212/01.wnl.0000334295.50403.4c 10.2217/14622416.9.11.1617 10.1111/j.1528-1167.2007.01022.x 10.2340/00015555-0528 10.2217/14622416.7.6.813 10.2174/157488606777934459 10.2165/00002018-199921060-00005 10.2217/17410541.2.3.225 10.1038/sj.tpj.6500356 10.1111/j.1469-1809.1955.tb01285.x 10.1007/BF03165106 10.1016/S1607-551X(09)70045-2 10.1111/j.1346-8138.2008.00548.x 10.1111/1523-1747.ep12388434 10.1034/j.1399-0039.2001.580102.x 10.1097/FPC.0b013e3282f3ef9c 10.1016/j.jaci.2004.07.047 10.1038/428486a 10.1097/FPC.0b013e32832c347d 10.1001/jama.291.5.605 10.1111/j.1468-3083.2008.02988.x 10.1016/j.eplepsyres.2008.04.003 10.1055/s-2008-1079336 10.1212/01.wnl.0000261917.83337.db 10.1038/nm.1884 10.1016/S1081-1206(10)61103-9 10.1111/j.1528-1167.2008.01719.x 10.1097/01.fpc.0000199500.46842.4a 10.2165/00023210-200822090-00003 10.1038/sj.jid.5701033 10.1212/01.WNL.0000156354.20227.F0 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 Future Medicine Ltd. 2010 Future Medicine Ltd |
| Copyright_xml | – notice: COPYRIGHT 2010 Future Medicine Ltd. – notice: 2010 Future Medicine Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO EHMNL FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7U7 8FD C1K FR3 P64 RC3 7X8 |
| DOI | 10.2217/pgs.09.162 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea UK & Ireland Database (ProQuest) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database (ProQuest) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library UK & Ireland Database ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Genetics Abstracts Engineering Research Database Technology Research Database Toxicology Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Central Student Genetics Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1744-8042 |
| EndPage | 356 |
| ExternalDocumentID | 2015683361 A225045944 20235791 10_2217_pgs_09_162 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | - 0R 0VX 123 29O 3V. 4.4 53G 70G 7X7 88E 8AO 8FE 8FH 8FI 8FJ ABFLS ABUWG ACDCL ACGFS ACPRK ADBBV AENEX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS BBAFP BBNVY BENPR BHPHI BPHCQ BVXVI CS3 DU5 EBS EHMNL EJD F5P FYUFA HCIFZ HZ IAO IEA IHR ITC LK8 M1P M7P MV1 NTCAX O9- OVD P2P PQEST PQQKQ PQUKI PRINS PROAC PSQYO RFM ZA5 --- 0R~ AAWFG AAYOK AAYXX ABJNI ACWKX AFFYO ALIPV CCPQU CITATION H13 HMCUK HZ~ M4Z PHGZM PHGZT RPM TDBHL TEORI TFL TFMDE TMEDX UKHRP CGR CUY CVF ECM EIF NPM PMFND 7XB 8FK ABNDM AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQGLB 7U7 8FD C1K FR3 P64 PUEGO RC3 7X8 |
| ID | FETCH-LOGICAL-c526t-5ed78d9b8879df013e432ba31f98a5178713d50658bc60d3e0c30a57c1505e5a3 |
| IEDL.DBID | BENPR |
| ISSN | 1462-2416 1744-8042 |
| IngestDate | Fri Sep 05 09:12:21 EDT 2025 Fri Sep 05 14:12:00 EDT 2025 Fri Jul 25 19:13:19 EDT 2025 Tue Jun 17 21:44:57 EDT 2025 Tue Jun 10 20:18:07 EDT 2025 Thu Apr 03 06:55:00 EDT 2025 Tue Jul 01 01:07:46 EDT 2025 Thu Apr 24 22:53:06 EDT 2025 Tue Jan 05 21:38:58 EST 2021 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c526t-5ed78d9b8879df013e432ba31f98a5178713d50658bc60d3e0c30a57c1505e5a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 20235791 |
| PQID | 228300832 |
| PQPubID | 54549 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_733349436 proquest_miscellaneous_1034830016 proquest_journals_228300832 gale_infotracmisc_A225045944 gale_infotracacademiconefile_A225045944 pubmed_primary_20235791 crossref_primary_10_2217_pgs_09_162 crossref_citationtrail_10_2217_pgs_09_162 futurescience_futuremedicine_10_2217_pgs_09_162 |
| ProviderPackageCode | RFM NTCAX 70G CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-March-01 2010-03-00 2010-Mar 20100301 |
| PublicationDateYYYYMMDD | 2010-03-01 |
| PublicationDate_xml | – month: 03 year: 2010 text: 2010-March-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Pharmacogenomics |
| PublicationTitleAlternate | Pharmacogenomics |
| PublicationYear | 2010 |
| Publisher | Future Medicine Ltd |
| Publisher_xml | – name: Future Medicine Ltd |
| References | e_1_3_3_3_15_1 e_1_3_3_3_16_1 e_1_3_3_3_13_1 e_1_3_3_3_14_1 e_1_3_3_3_19_1 e_1_3_3_3_17_1 e_1_3_3_3_18_1 e_1_3_3_3_5_1 e_1_3_3_3_4_1 e_1_3_3_3_3_1 e_1_3_3_3_2_1 e_1_3_3_3_9_1 e_1_3_3_3_22_1 e_1_3_3_3_23_1 e_1_3_3_3_8_1 e_1_3_3_3_7_1 e_1_3_3_3_20_1 e_1_3_3_3_6_1 e_1_3_3_3_21_1 e_1_3_3_3_1_1 e_1_3_3_3_27_1 e_1_3_3_3_26_1 e_1_3_3_3_25_1 e_1_3_3_3_24_1 e_1_3_3_3_29_1 e_1_3_3_3_28_1 e_1_3_3_3_30_1 e_1_3_3_3_11_1 e_1_3_3_3_34_1 e_1_3_3_3_12_1 e_1_3_3_3_33_1 e_1_3_3_3_32_1 e_1_3_3_3_10_1 e_1_3_3_3_31_1 |
| References_xml | – ident: e_1_3_3_3_21_1 doi: 10.1159/000091834 – ident: e_1_3_3_3_24_1 doi: 10.1073/pnas.0409500102 – ident: e_1_3_3_3_17_1 doi: 10.1212/01.wnl.0000334295.50403.4c – ident: e_1_3_3_3_29_1 doi: 10.2217/14622416.9.11.1617 – ident: e_1_3_3_3_14_1 doi: 10.1111/j.1528-1167.2007.01022.x – ident: e_1_3_3_3_31_1 doi: 10.2340/00015555-0528 – ident: e_1_3_3_3_30_1 doi: 10.2217/14622416.7.6.813 – ident: e_1_3_3_3_4_1 doi: 10.2174/157488606777934459 – ident: e_1_3_3_3_16_1 doi: 10.2165/00002018-199921060-00005 – ident: e_1_3_3_3_12_1 doi: 10.2217/17410541.2.3.225 – ident: e_1_3_3_3_13_1 doi: 10.1038/sj.tpj.6500356 – ident: e_1_3_3_3_26_1 doi: 10.1111/j.1469-1809.1955.tb01285.x – ident: e_1_3_3_3_22_1 doi: 10.1007/BF03165106 – ident: e_1_3_3_3_33_1 doi: 10.1016/S1607-551X(09)70045-2 – ident: e_1_3_3_3_23_1 – ident: e_1_3_3_3_32_1 doi: 10.1111/j.1346-8138.2008.00548.x – ident: e_1_3_3_3_5_1 doi: 10.1111/1523-1747.ep12388434 – ident: e_1_3_3_3_25_1 doi: 10.1034/j.1399-0039.2001.580102.x – ident: e_1_3_3_3_27_1 doi: 10.1097/FPC.0b013e3282f3ef9c – ident: e_1_3_3_3_8_1 doi: 10.1016/j.jaci.2004.07.047 – ident: e_1_3_3_3_10_1 doi: 10.1038/428486a – ident: e_1_3_3_3_28_1 doi: 10.1097/FPC.0b013e32832c347d – ident: e_1_3_3_3_34_1 doi: 10.1001/jama.291.5.605 – ident: e_1_3_3_3_20_1 doi: 10.1111/j.1468-3083.2008.02988.x – ident: e_1_3_3_3_18_1 doi: 10.1016/j.eplepsyres.2008.04.003 – ident: e_1_3_3_3_1_1 doi: 10.1055/s-2008-1079336 – ident: e_1_3_3_3_3_1 doi: 10.1212/01.wnl.0000261917.83337.db – ident: e_1_3_3_3_9_1 doi: 10.1038/nm.1884 – ident: e_1_3_3_3_19_1 doi: 10.1016/S1081-1206(10)61103-9 – ident: e_1_3_3_3_15_1 doi: 10.1111/j.1528-1167.2008.01719.x – ident: e_1_3_3_3_11_1 doi: 10.1097/01.fpc.0000199500.46842.4a – ident: e_1_3_3_3_2_1 doi: 10.2165/00023210-200822090-00003 – ident: e_1_3_3_3_7_1 doi: 10.1038/sj.jid.5701033 – ident: e_1_3_3_3_6_1 doi: 10.1212/01.WNL.0000156354.20227.F0 |
| SSID | ssj0021640 |
| Score | 2.4087288 |
| Snippet | Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson... Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are associated with a high incidence of Stevens-Johnson... |
| SourceID | proquest gale pubmed crossref futurescience |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 349 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Alleles Antibiotics Anticonvulsants Anticonvulsants - adverse effects antiepileptic drugs Asian Continental Ancestry Group - genetics Carbamazepine - adverse effects Carbamazepine - analogs & derivatives Case-Control Studies Child Complications and side effects cutaneous adverse drug reaction Demographic aspects Dosage and administration Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - immunology Female Genetic aspects Genetic Association Studies Genetic susceptibility HLA Antigens - genetics HLA susceptibility HLA-B Antigens - genetics HLA-B15 Antigen Humans lamotrigine Male Middle Aged oxcarbazepine Pharmacogenetics phenytoin Phenytoin - adverse effects Risk Factors Stevens-Johnson syndrome Stevens-Johnson Syndrome - chemically induced Stevens-Johnson Syndrome - etiology Stevens-Johnson Syndrome - genetics Stevens-Johnson Syndrome - immunology Taiwan Toxic epidermal necrolysis Triazines - adverse effects Young Adult |
| Title | Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese |
| URI | http://dx.doi.org/10.2217/pgs.09.162 https://www.ncbi.nlm.nih.gov/pubmed/20235791 https://www.proquest.com/docview/228300832 https://www.proquest.com/docview/1034830016 https://www.proquest.com/docview/733349436 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdr-jIYY9912xWNjY5BRWzLku2n0Y2WMFgJo4W8CVlSSiHYWZxA-7Y_fXeW7JKt22PQyYp9ug_Zd78fIR9skltnpWWVFZJlEKBYyR0Y3pwLm1htZYH9zt8v5OQq-zYTs1Cb04ayyt4ndo7aNgbfkY87pCrIF9LPy58MSaPw42pg0Nghu-CBCzEiu1_OLqY_hhMXnAVi316UMghV0uOTppCGj5fXLQKcJjLdikhPPJRHCD9_--k_ss8uCp0_I09D-khPvb6fk0eufkGOpx5_-u6EXt63U7Un9JhO75Gp716SX9gO0tQU68kpkqgsHL2pqV41HXArhad845bgJ8CPGGZXm2sYtqB8Sz37WcsCoxbtkQ5gjqXr5hZmOySbhdUWtIZctOmwTvDyE11TpOl2rXtFrs7PLr9OWKBgYEakcs2Es3lhywpcUWnn-Mo042mleTIvCy0SsPaEW4FpTGVkbLmLDY-1yA3kmcIJzV-TUd3Ubo_QKjau1Jpn1ohM27xKRCUy_BgviyqelxH51KtBmYBPjjQZCwXnFFSZApWpuFSgsoi8H2SXHpXjQanxljaV_9UXLTw44yPqW6Fxw9pGhx4FuAOEyVKnKSK-iTLLInK4JQlGabaGD_odo4JTaNWwhSPybhjFiVjnVrtm08Jf4hkKJTIi9B8yOeeIKcRB5I3fi8MzSDv0ojLZ_-_yB-Sxr4HASrpDMlqvNu4tpFbr6ojs5LP8KJjRb-adJr4 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfG9gASQnxTNsAIGJq0qEkcO_UDQgM2dWyrKtRJezOO7U6TqqQ0raBv_EP8j9zFSabC4G2Pkc9xkvu0c_c7Ql7bKLXOChtklosgAQcVSOZA8caM28hqK3pY73wyEP3T5PMZP1sjv5paGEyrbGxiZahtYfCMvFshVUG8EL-ffguwaRT-XG06aHipOHLL77BjK98dfgL2vonjg_3Rx35QNxUIDI_FPODOpj0rM1Auacd4CJiwONMsGsue5hHIb8QsR8ecGRFa5kLDQs1TA5ETd1wzuO8NsgFRhgQl2viwPxh-aXd4sPcIfTlTHIBrFB4PNYawvzs9LxFQNRLxige87aFDanf3t1_4I9qtvN7BXXKnDlfpnpeve2TN5ffJ9tDjXS936eiyfKvcpdt0eImEvXxAfmL5SZFTzF-n2LRl4uhFTvWsqIBiKXD1wk3BLoHdMoGdLc5h2IKwWeq7rZVB3cGLNsgKMMfSefEDZjtsbgurTWgOsW9RYavg7fs6p9gW3JXuITm9Fu48Iut5kbsnhGahcVJrlljDE23TLOIZT_Dnv-hl4Vh2yE7DBmVqPHRsyzFRsC9ClilgmQqlApZ1yKuWdupRQK6k6q5wU_mrJkniyhlvkd8KjQmsbXRdEwFvgLBcai9GhDkuk6RDtlYowQiYleHNRmJUbYRK1apMh7xsR3Ei5tXlrliU8EgsQaJIdAj9B03KGGIYMSB57GWx_QZxhZYko6f_Xf4FudkfnRyr48PB0Sa55fMvMItvi6zPZwv3DMK6efa8ViZKvl63_v4GWkVhcA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTkJICPFN2QAjYAhpUZM4TpoHhAZb1TGoKrRJezOO7UyTqqQ0raBv_Fv8d9zFSafC4G2Pkc9x0vtO734H8NIEibEmNl5mROxF6KC8lFtUvJwLExhl4j71O38excOT6OOpON2AX20vDJVVtjaxNtSm1PSNvFcjVWG8EPbypipivD94N_3m0QAp-qO1nabhJOTILr9j9la9PdxHVr8Kw8HB8Yeh1wwY8LQI47knrEn6Js1Q0VKT0wfBiIeZ4kGe9pUIUJYDbgQ56UzHvuHW19xXItEYRQkrFMf7XoPNBJ1ivwOb7w9G4y-rbA_zEN-1NoUeusnYYaOGmAL0pmcVgasGcbjmDW86GJHG9f3tI_6IfGsPOLgNt5rQle05WbsDG7a4Cztjh3293GXHF61c1S7bYeMLVOzlPfhJrShlwaiWndEAl4ll5wVTs7IGjWXI4XM7RRuFNkx7ZrY4w2WDgmeYm7xWec00L9aiLOAew-blD9xtadAtnjZhBcbBZY2zQrcfqoLRiHBb2ftwciXceQCdoizsI2CZr22qFI-MFpEySRaITERUCBD3Mz9Pu_CmZYPUDTY6jeiYSMyRiGUSWSb9VCLLuvBiRTt1iCCXUvXWuCndVVswcemO18RvSYYFz9aq6Y_ANyCILrkXEtqcSKOoC9trlGgQ9NryVisxsjFIlVypTxeer1ZpI9XYFbZcVPhIPCKiIO4C-wdNwjnhGXEkeehkcfUbhDVyUho8_u_xz-A66q38dDg62oIbrhSDCvq2oTOfLewTjPDm2dNGlxh8vWr1_Q2n72Wc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Common+risk+allele+in+aromatic+antiepileptic-drug+induced+Stevens-Johnson+syndrome+and+toxic+epidermal+necrolysis+in+Han+Chinese&rft.jtitle=Pharmacogenomics&rft.au=Hung%2C+Shuen-Iu&rft.au=Chung%2C+Wen-Hung&rft.au=Liu%2C+Zhi-Sheng&rft.au=Chen%2C+Chien-Hsiun&rft.date=2010-03-01&rft.eissn=1744-8042&rft.volume=11&rft.issue=3&rft.spage=349&rft_id=info:doi/10.2217%2Fpgs.09.162&rft_id=info%3Apmid%2F20235791&rft.externalDocID=20235791 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-2416&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-2416&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-2416&client=summon |